Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk
- Authors: Naumov AV1, Tkacheva ON1, Khovasova NO1
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Department of diseases of aging. Russian clinical investigator center of gerontologies
- Issue: Vol 91, No 1 (2019)
- Pages: 108-113
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32955
- DOI: https://doi.org/10.26442/00403660.2019.01.000039
- ID: 32955
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A V Naumov
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Department of diseases of aging. Russian clinical investigator center of gerontologies
Email: nanton78@gmail.com
д.м.н., зав. лаб. заболеваний костно-мышечной системы Российского геронтологического научно-клинического центра Moscow, Russia
O N Tkacheva
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Department of diseases of aging. Russian clinical investigator center of gerontologiesд.м.н., проф., зав. каф. болезней старения ФДПО «РНИМУ им. Н.И. Пирогова»; директор Российского геронтологического научно-клинического центра Moscow, Russia
N O Khovasova
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Department of diseases of aging. Russian clinical investigator center of gerontologiesк.м.н., доцент каф. болезней старения ФДПО «РНИМУ им. Н.И. Пирогова»; н.с. лаб. заболеваний костно-мышечной системы Российского геронтологического научно-клинического центра Moscow, Russia
References
- Голубев В.Л., Данилов А.Б., Вейн А.М. Психосоциальные факторы, гендер и боль. Журнал неврологии и психиатрии им. С.С. Корсакова. 2004;104(11):70-3.
- Nijs J, Malfliet A, Ickmans K. Treatment of central sensitization in patients with «unexplained» chronic pain: an update Expert. Opin Pharmacother. 2014;15(12):1671-83.
- Smith S.R, Deshpande B.R, Collins J.E, et al. Comparative pain reduction of oral non - steroidal anti - inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962-72. doi: 10.1016/j.joca.2016.01.135
- Gargallo C.J, Sostres C, Lanas А. Prevention and Treatment of NSAID Gastropathy. A. Curr Treat Options Gastro. 2014;12:398. doi: 10.1007/s119 38-014-0029-4
- Amer M, Bead V.R, Bathon J, Blumenthal R.S, Edwards D.N. Use of nonsteroidal anti - inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiology in Review. 2010;18(4):204-12. doi: 10.1097/crd.0b013e3181ce1521
- Насонов Е.Л., Лабезник Л.Б., Беленков Ю.Н. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: Алмаз, 2006.
- Каратеев А.Е. Возможность использования НПВП у больных с ЖКТ и кардиоваскулярными факторами риска. РМЖ. 2009;17(7):495-503.
- Warner T.D, Mitchel J.A. Cycloxygenase; new isoforms, new inhibitors, and new lessons from clinic. FASEB J. 2004;18:790-804. doi: 10.1096/fj.03-0645rev
- Solomon S.D, et al. for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-80. doi: 10.1097/01.aog.0000166692.14982.d1
- Elliot M. Antman A.H. A Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation. 2007;115:1634-42.
- Lanas A, Tornero J, Zamorano J.L. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010 Aug;69(8):1453-8. doi: 10.1136/ ard.2009.123166
- Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti - inflammatory drugs. Expert Opin Drug Saf. 2006;5:83-94. doi: 10.1517/14740338.5.1.83
- Atiquzzaman M, Kopec J, Karim M.E, Wong H, Anis A. The role of nsaids in the association between osteoarthritis and cardiovascular diseases: a population - based cohort study. Ann Rheum Dis. 2018;77(Suppl):A144. [European League Against Rheumatism (EULAR) Congress 2018: Abstract OP0190].
- Gomez-Lumbreras A, Vives R, Giner-Soriano M, Pera H, Fradera M, Marsal J.R, Morros R. Analgesic drugs and risk of ischaemic stroke in patients with ostheoartritis: a real world data case - control study. Ann Rheum Dis. 2018;77(Suppl):A1722. [European League Against Rheumatism (EULAR) Congress 2018: Abstract AB1253].
- Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P.M, et al. Cardiovascular safety of non - steroidal anti - inflammatory drugs: network meta - analysis. BMJ. 2011(Jan 11);342:7086. doi: 10.1136/bmj.c7086
- Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23.
- Оганов Р.Г., Денисов И.Н., Симаненков В.И. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56. doi: 10.15829/1728-8800-2017-6-5-56
- Food and Drug Administration [Internet]. Silver Spring, MD. FDA Briefing Information for the February 10-11, 2014 Joint Meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee.
- Drug Safety Update. 2013 June;6(11):A2.
- Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost. 2009;35:150-7. doi: 10.1055/s-0029-1220323
- Tantry U.S, Bliden K.P, Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705-9. doi: 10.1016/j.jacc.2005.05.090
- Bowbrick V.A, Mikhailidis D.P, Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost. 2003;9:137-42. doi: 10.1177/107602960300900208
- Craft R.M, Chavez J.J, Bresee S.J, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med. 2004;143:301-9. doi: 10.1016/j.lab.20 04.01.011
- Bailey L.A, Sistino J.J, Uber W.E. Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors? J Extra Corpor Technol. 2005;37:43-7.
- de Abajo F.J, Gil M.J, Poza P.G, Bryant V, Oliva B, Timoner J, García-Rodríguez L.A. Risk of nonfatal acute myocardial infarction associated with nonsteroidal antiinflammatory drugs, non - narcotic analgesics and other drugs used in osteoarthritis: a nested case - control study. Pharmacoepidemiology and Drug Safety. 2014. doi: 10.1002/pds
- Lúcio S.M, Ferreira H, Lima J, Reis S. Interactions between Oxicams and Membrane Bilayers: an Explanation for Their Different COX. Medicinal Chemistry. 2006;2:447-56. doi:2174/157340606778250199
- Arfè A, Scotti L, Varas-Lorenzo C, et al. Non - steroidal anti - inflammatory drugs and risk of heart failure in four European countries: nested case - control study. BMJ. 2016; p. 354-4857. doi: 10.1136/bmj.i4857
- Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999;48(7):369-79. doi: 10.1007/s000110050474
- Bjordal J.M, Klovning A, Ljunggren A.E, et al. Short - term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta - analysis of randomised placebo - controlled trials. Eur J Pain. 2007;11:125-38. doi: 10.1016/j.ejpain.2006.02.013
- Kullich W, Klein G. Influence of the nonsteroidal antiinflammatory drug lornoxicami. v. on the secretion of the endogenous opiate peptides dynorphin and β - endorphin. Aktuel Rheumatol. 1992;17(4):128-32. doi: 10.1055/s-2008-1047362
- Radhofer-Welte S, Rabasseda X. Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000;36(1):55-76. doi: 10.1358/dot.2000.36.1.566627
- Parada L, Marstein J.P, Danilov A. Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain. Pain Manag. 2016 Oct;6(5):445-54. doi: 10.2217/pmt.16.7